Holen Sie sich die Stockscreener-App
4.01
1.47%
-0.06
Schlusskurs vom Vortag:
$4.07
Offen:
$4.13
24-Stunden-Volumen:
1.65M
Relative Volume:
1.10
Marktkapitalisierung:
$387.86M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-81.49M
KGV:
-4.9567
EPS:
-0.809
Netto-Cashflow:
$-73.48M
1W Leistung:
+2.82%
1M Leistung:
-12.06%
6M Leistung:
+28.53%
1J Leistung:
-56.37%
1-Tages-Spanne:
$3.965
$4.20
1-Wochen-Bereich:
$3.76
$4.57
52-Wochen-Spanne:
$1.07
$11.46
Rezolute Inc Stock (RZLT) Company Profile
Firmenname
Rezolute Inc
Sektor
Branche
Telefon
650-206-4507
Adresse
275 SHORELINE DRIVE, SUITE 500, REDWOOD CITY
Compare RZLT vs VRTX, MRNA, REGN, ARGX, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RZLT
Rezolute Inc
|
4.01 | 377.22M | 0 | -81.49M | -73.48M | -0.809 |
VRTX
Vertex Pharmaceuticals Inc
|
504.73 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
190.01 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
735.20 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.21 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
206.64 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Rezolute Inc Stock (RZLT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-25 | Hochstufung | Wedbush | Neutral → Outperform |
| 2025-12-11 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2025-12-11 | Herabstufung | Craig Hallum | Buy → Hold |
| 2025-12-11 | Herabstufung | Wedbush | Outperform → Neutral |
| 2024-11-05 | Eingeleitet | Wedbush | Outperform |
| 2024-08-27 | Eingeleitet | Guggenheim | Buy |
| 2024-07-17 | Eingeleitet | BTIG Research | Buy |
| 2024-06-04 | Eingeleitet | Craig Hallum | Buy |
| 2024-04-09 | Eingeleitet | Maxim Group | Buy |
| 2022-08-02 | Fortgesetzt | Canaccord Genuity | Buy |
| 2022-06-15 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2021-09-08 | Eingeleitet | ROTH Capital | Buy |
| 2021-05-27 | Eingeleitet | Oppenheimer | Outperform |
| 2021-05-25 | Eingeleitet | H.C. Wainwright | Buy |
Alle ansehen
Rezolute Inc Aktie (RZLT) Neueste Nachrichten
Rezolute Inc. R (6HV1.DU) Stock Price, News, Quote & History - Yahoo! Finance Canada
Rezolute Initiated at Buy by Lake Street - Moomoo
Rezolute Inc (NASDAQ: RZLT) Share Price, RZLT Stock News, RZLT Share Price & Updates - kalkine.ca
RZLT Initiated Coverage by Lake Street -- Price Target Announced at $9.00 - GuruFocus
Rezolute stock rating upgraded to Buy at Craig-Hallum on trial data - Investing.com Nigeria
RZLT Upgraded by Craig-Hallum -- Price Target Raised to $7.00 - GuruFocus
Rezolute highlights ENDO data on congenital HI outcomes and tumor HI case series - scanx.trade
H.C. Wainwright raises Rezolute stock price target on trial data - Investing.com
Rezolute, Inc. (RZLT) Stock Price, News, Quote & History - Yahoo! Finance Canada
RZLT Maintained by HC Wainwright & Co. -- Price Target Raised to $10 - GuruFocus
Rezolute (NASDAQ:RZLT) Given New $10.00 Price Target at HC Wainwright - MarketBeat
HC Wainwright & Co. maintains Buy rating on Rezolute, $10 price target - TradingView
Citizens reiterates Rezolute stock rating on tumor trial results due By Investing.com - Investing.com Canada
Citizens reiterates Rezolute stock rating on tumor trial results due - Investing.com
Rezolute Inc (RZLT) Faces Valuation Challenges Amid Cash Burn an - GuruFocus
Rezolute Q4FY26 Results: EPS misses estimate at $(0.20), net loss narrows - scanx.trade
Rezolute, Inc. FY 2026: Revenue $0 Net loss $77.6M, EPS $(0.75) — 10-K Summary - TradingView
Rezolute Fiscal Q4 Loss Narrows - marketscreener.com
Rezolute reports FY2026 net loss $77.6M, cash and investments $107.8M as of June 30, 2026 - TradingView
Rezolute Reports Fourth Quarter and Full Year Fiscal 2026 Financial Results and Provides Business Update - The Manila Times
Rezolute Reports $20.5 Million Fourth-Quarter Loss and $107.8 Million Cash - Quiver Quantitative
Rezolute Q4 net loss narrows as R&D expenses fall - TradingView
Press Release: Rezolute Reports Fourth Quarter and Full Year Fiscal 2026 Financial Results and Provides Business Update - Moomoo
Rezolute Inc (RZLT) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Should I Buy RZLT? RZLT 2026 AnalysisIntellectia AI™ - Intellectia AI
Rezolute Inc. (RZLT) Q2 2026 Earnings: Narrower-Than-Expected Loss Offers Modest BeatOne-Time Loss Impact - careplusvn.com
Rezolute Inc. (NV) (RZLT) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Weekly Recap: Strong retention in sunRIZE extension and buy‑tilt at $6 - TradingView
Rezolute, Inc. expected to post a loss of 15 cents a shareEarnings Preview - TradingView
Rezolute: Initiating At Sell Despite Attempts To Rescue Ersodetug Following sunRIZE Upset - Seeking Alpha
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Rezolute (RZLT) FDA Review Highlights Uncertain Path Amid Cash-F - GuruFocus
Rezolute says late-stage trial data for lead asset remains under FDA review - TradingView
Rezolute awaits FDA feedback on congenital HI treatment data By Investing.com - Investing.com Nigeria
Rezolute FDA Review Continues After Phase 3 sunRIZE Study Missed Primary Endpoint - Yahoo Finance
Rezolute (RZLT) Updates FDA Review of Phase 3 Data Amid Unprofitable Status - GuruFocus
Rezolute awaits FDA feedback on congenital HI treatment data - investing.com
Rezolute Provides Update on FDA Review of its Phase 3 sunRIZE Study Results in Congenital Hyperinsulinism - The Manila Times
RZLT Q4'26 Earnings: EPS estimate is (0.15) USD - TradingView
FDA is still reviewing Rezolute’s experimental drug. No timeline is set. - Stock Titan
symbol__ Stock Quote Price and Forecast - CNN
Rezolute Stock Price Forecast. Should You Buy RZLT? - StockInvest.us
Rezolute (RZLT) CCO sells stock to cover RSU taxes - stocktitan.net
RZLT Q4'26 Earnings: revenue estimate is 0 USD - tradingview.com
Rezolute (RZLT) Shares Decline 7% as Stock Approaches Key Support at $4.39Diagonal Spread Trade - vinanet.vn
Wedbush Maintains Rezolute(RZLT.US) With Buy Rating, Maintains Target Price $6 - Moomoo
Rezolute, Inc.'s (NASDAQ:RZLT) Shift From Loss To Profit - Simply Wall Street
Balyasny Asset Management L.P. Reduces Stake in Rezolute Inc (RZ - GuruFocus
Rezolute, Inc. (NASDAQ:RZLT) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Rezolute Number of Employees 2026 | Employee Count & Headcount Data - Revelio Labs
Bank of New York Mellon Corp Sells 481,913 Shares of Rezolute, Inc. $RZLT - MarketBeat
Finanzdaten der Rezolute Inc-Aktie (RZLT)
Umsatz
Nettogewinn
Free Cashflow
ENV
Rezolute Inc-Aktie (RZLT) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Hogenhuis Wladimir | Director |
Dec 16 '25 |
Buy |
1.69 |
5,650 |
9,548 |
119,675 |
| ROBERTS BRIAN KENNETH | Chief Medical Officer |
Dec 16 '25 |
Buy |
1.70 |
28,000 |
47,600 |
308,352 |
| Evans Daron | CFO |
Dec 15 '25 |
Buy |
1.77 |
40,000 |
70,640 |
415,900 |
| Evans Daron | CFO |
Dec 15 '25 |
Buy |
1.79 |
5,000 |
8,938 |
7,000 |
| Elam Nevan C | CEO |
Dec 15 '25 |
Buy |
1.59 |
32,000 |
50,880 |
641,119 |
| Karnawat Sunil Ratilal | Chief Commercial Officer |
Dec 15 '25 |
Buy |
1.62 |
12,100 |
19,599 |
71,542 |
| Evans Daron | CFO |
Dec 09 '25 |
Buy |
5.04 |
10,549 |
53,167 |
131,900 |
0.05%
0.82%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):